QIAGEN Profit Margin 2010-2022 | QGEN

Current and historical gross margin, operating margin and net profit margin for QIAGEN (QGEN) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. QIAGEN net profit margin as of September 30, 2022 is 20.83%.
QIAGEN Annual Profit Margins
QIAGEN Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $11.167B $2.252B
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $171.581B 10.47
GSK (GSK) United Kingdom $71.504B 8.96
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
Ginkgo Bioworks Holdings (DNA) United States $3.492B 0.00
Myovant Sciences (MYOV) United Kingdom $2.595B 0.00
Arcus Biosciences (RCUS) United States $2.459B 36.91
Biohaven (BHVN) United States $1.112B 0.00
Emergent Biosolutions (EBS) United States $0.588B 4.62
Zymeworks (ZYME) Canada $0.480B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.270B 0.00
Enzo Biochem (ENZ) United States $0.092B 0.00
SQZ Biotechnologies (SQZ) United States $0.042B 0.00
Gelesis Holdings (GLS) United States $0.032B 0.00
Ambrx Biopharma (AMAM) United States $0.020B 0.00